CCC Live Cases > Structural heart > Transfemoral ViV TAVR using 23mm Evolut Pro+ Valve with Sentinel Cerebral Embolic Protection Device – May 2021

Transfemoral ViV TAVR using 23mm Evolut Pro+ Valve with Sentinel Cerebral Embolic Protection Device – May 2021

Case & Plan:
73-year-old male presents with worsening NYHA Class III symptoms of heart failure for the last 4-5 months. Past medical history is significant for severe restrictive lung disease, home oxygen use, HTN, HLD, IDDM, OA, CAD and aortic stenosis s/p AVR and CABG (in 2012 with 21mm MitroFlow bio-prosthetic valve and LIMA to LAD, SVG to OM, RPDA, RPL). Recent TT echocardiogram revealed LVEF of 46%, moderate TR/MR, abnormal aortic bio-prosthesis with moderate to severe regurgitation and mean gradient of 25mmHg. His STS PROM risk for redo-AVR was calculated at 9.3%. Heart Team evaluation found him to be at high risk for SAVR. Now planned for trans-femoral ViV TAVR via right percutaneous femoral arterial access using a 23mm Evolut Pro + valve with Sentinel cerebral embolic protection device.

Comments

One Comment
Ophelia Powell Torres. St Thomas USVI
11 May, 2021

Hello Dr. Sharma and. Kini. I was one of your regulars yo the June conferences. I miss those conferences. Now I think I need to come and see you for myself. Very good presentation

Reply

Leave a Reply

Your email address will not be published.*


Warning: Invalid argument supplied for foreach() in /home/468933.cloudwaysapps.com/wrezgzxbge/public_html/wp-content/plugins/constant-contact-forms/includes/class-settings.php on line 1087

Yes, I would like to receive emails from Mount Sinai Hospital. Sign me up!


By submitting this form, you are consenting to receive marketing emails from: Mount Sinai Hospital, One Gustave L. Levy Place, Box, New York, NY, 10029, https://ccclivecases.org. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact